The SGLT2 inhibitor dapagliflozin is well tolerated regardless of diabetes status according to new analyzes from the DARE-19 study in adults who were hospitalized with COVID-19.
The key results from DARE-19, first presented in May, showed that dapagliflozin (Farxiga, AstraZeneca) did not significantly reduce the risk of organ failure or death or recovery in adults hospitalized with COVID-19 No improvement compared to placebo, although the data showed lower event numbers in patients treated with dapagliflozin compared to placebo. However, the ever-evolving dynamics of the COVID-19 pandemic made it difficult to capture a large number of events in DARE-19 as the standard of care for hospital patients improved rapidly and fewer hospital patients were reported to have suffered organ failure or death, according to Mikhail Kosiborod, MD, FACC, FAHA, a Cardiologist at Saint Luke’s Mid America Heart Institute and Professor of Medicine at the University of Missouri-Kansas City School of Medicine.
In new analyzes presented at the American Diabetes Association’s Scientific Sessions, the researchers showed that these observations were consistent in patients with type 2 diabetes – about half of the patients in the study – and those without type 2 diabetes . In addition, patients treated with dapagliflozin had fewer numerical side effects during the study than patients who received placebo. This included events with acute kidney damage and was also consistent in patients with and without type 2 diabetes.
Read the full Healio article: DARE-19: Dapagliflozin well tolerated for inpatient COVID-19 with, without diabetes
